Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HTHQ (HTHQ(1-O-Hexyl-2,3,5-trimethylhydroquinone)) 是一种强力的亲脂性酚类抗氧化剂。它通过与活性氧直接反应,清除 ROS,从而形成更稳定的自由基,具有很强的抗氧化活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 279 | 现货 | ||
10 mg | ¥ 393 | 现货 | ||
25 mg | ¥ 658 | 现货 | ||
50 mg | ¥ 788 | 现货 | ||
100 mg | ¥ 1,230 | 现货 | ||
200 mg | ¥ 1,850 | 现货 | ||
500 mg | ¥ 3,130 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 293 | 现货 |
产品描述 | HTHQ (HTHQ(1-O-Hexyl-2,3,5-trimethylhydroquinone)), a hydroquinone monoalkyl ether, is an effective anti-oxidative agent. HTHQ is a potent anti-lipid-peroxidative compound and its antioxidation activity to be extremely elevated in biological systems, such as that of liver microsomes via the generation of stable free radicals. |
体外活性 | HTHQ has an anti-oxidative activity similar to D,L-alpha-tocopherol against lipid peroxidation in linolate micelles initiated by addition of Fe2+. The anti-lipid-peroxidation activity of HTHQ is higher 4.8-fold than that of D,L-alpha-tocopherol against the peroxidation in phosphatidylcholine liposomes initiated by addition of Fe2+. [1] The effects of 0.02% Glu-P-1 or 0.03% MeIQx on the number and area of foci is significantly reduced by 0.125% HTHQ. [2] |
体内活性 | Treatment with HTHQ potently inhibits PhIP-induced mammary carcinogenesis in female rats. Compared with DMN-induced hepatic fibrosis animals in the liver tissue, HTHQ reduced mRNA level of PDGF (Platelet-derived growth factor), α-SMA (α-smooth muscle actin) and TGF-β (transforming growth factor-β). In this study, we showed that HTHQ improves against DMN-induced liver fibrosis in male SD rats. |
别名 | HX 1171, HTHQ(1-O-Hexyl-2,3,5-trimethylhydroquinone), 1-O-hexyl-2,3,5-trimethylhydroquinone |
分子量 | 236.35 |
分子式 | C15H24O2 |
CAS No. | 148081-72-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 43 mg/mL(181.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.231 mL | 21.1551 mL | 42.3101 mL | 105.7753 mL |
5 mM | 0.8462 mL | 4.231 mL | 8.462 mL | 21.1551 mL | |
10 mM | 0.4231 mL | 2.1155 mL | 4.231 mL | 10.5775 mL | |
20 mM | 0.2116 mL | 1.0578 mL | 2.1155 mL | 5.2888 mL | |
50 mM | 0.0846 mL | 0.4231 mL | 0.8462 mL | 2.1155 mL | |
100 mM | 0.0423 mL | 0.2116 mL | 0.4231 mL | 1.0578 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HTHQ 148081-72-5 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species HX 1171 BTT 105 BTT105 inhibit BTT-105 HTHQ(1-O-Hexyl-2,3,5-trimethylhydroquinone) HX-1171 1-O-hexyl-2,3,5-trimethylhydroquinone Inhibitor HX1171 inhibitor